ReviewZoonoses and public health2012
How Ebola virus counters the interferon system.
Review in Zoonoses and public health, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Ebola virus disease: A persistent challenge in global health security.Open veterinary journal · 2026Review
- Superior replication, pathogenicity, and immune evasion of a Texas dairy cattle H5N1 virus compared to a historical avian isolate.Scientific reports · 2025Article
- Characterizing changes in transcriptome and kinome responses in testicular cells during infection by Ebola virus.Npj viruses · 2024Article
- Negative-Strand RNA Virus-Vectored Vaccines.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Macrophage infection, activation, and histopathological findings in ebolavirus infection.Frontiers in cellular and infection microbiology · 2022Review
- An Ebola,Computational and structural biotechnology journal · 2021Article
- Investigating host-virus interaction mechanism and phylogenetic analysis of viral proteins involved in the pathogenesis.PloS one · 2021Article
- Perspectives towards antiviral drug discovery against Ebola virus.Journal of medical virology · 2019Review
- Accurate characterization of the IFITM locus using MiSeq and PacBio sequencing shows genetic variation in Galliformes.BMC genomics · 2017Article
- Ebola Virus Infection: Overview and Update on Prevention and Treatment.Infectious diseases and therapy · 2015Article
- Interferon-Induced Transmembrane Protein-Mediated Inhibition of Host Cell Entry of Ebolaviruses.The Journal of infectious diseases · 2015Article
- miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression.Experimental cell research · 2015Article
- Primordial prevention: promoting preparedness for ebola virus disease.Journal of clinical and diagnostic research : JCDR · 2015Article
- Intracellular immunity: finding the enemy within--how cells recognize and respond to intracellular pathogens.Journal of leukocyte biology · 2014Article
- Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Infectious diseases of poverty · 2014Article
- Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga.The journal of venomous animals and toxins including tropical diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zoonotic transmission of Ebola virus (EBOV) to humans causes a severe haemorrhagic fever in afflicted individuals with high case-fatality rates. Neither vaccines nor therapeutics are at present available to combat EBOV infection, making the virus a potential threat to public health. To devise antiviral strategies, it is important to understand which components of the immune system could be effective against EBOV infection. The interferon (IFN) system constitutes a key innate defence against viral infections and prevents development of lethal disease in mice infected with EBOV strains not adapted to this host. Recent research revealed that expression of the host cell IFN-inducible transmembrane proteins 1-3 (IFITM1-3) and tetherin is induced by IFN and restricts EBOV infection, at least in cell culture model systems. IFITMs, tetherin and other effector molecules of the IFN system could thus pose a potent barrier against EBOV spread in humans. However, EBOV interferes with signalling events required for human cells to express these proteins. Here, we will review the strategies employed by EBOV to fight the IFN system, and we will discuss how IFITM proteins and tetherin inhibit EBOV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.